12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga · 05/13 17:06
Gainers
- HCW Biologics (NASDAQ:HCWB) stock increased by 173.1% to $14.23 during Tuesday's regular session. The market value of their outstanding shares is at $15.9 million.
- Xilio Therapeutics (NASDAQ:XLO) shares increased by 40.75% to $1.03. The market value of their outstanding shares is at $53.2 million. As per the news, the Q1 earnings report came out 3 days ago.
- CNS Pharma (NASDAQ:CNSP) shares rose 38.01% to $1.67. The market value of their outstanding shares is at $4.9 million.
- Humacyte (NASDAQ:HUMA) stock moved upwards by 33.33% to $1.76. The market value of their outstanding shares is at $273.0 million. The company's, Q1 earnings came out today.
- Apyx Medical (NASDAQ:APYX) stock moved upwards by 27.6% to $1.41. The market value of their outstanding shares is at $53.2 million. The company's, Q1 earnings came out 3 days ago.
- Celularity (NASDAQ:CELU) stock moved upwards by 27.57% to $1.94. The company's market cap stands at $46.1 million. The company's, Q4 earnings came out 3 days ago.
Losers
- Polyrizon (NASDAQ:PLRZ) stock decreased by 91.4% to $0.03 during Tuesday's regular session.
- Zhengye Biotechnology (NASDAQ:ZYBT) shares declined by 64.03% to $4.83. The market value of their outstanding shares is at $228.9 million.
- Accelerate Diagnostics (NASDAQ:AXDX) stock fell 38.48% to $0.08. The company's market cap stands at $2.0 million.
- Regencell Bioscience (NASDAQ:RGC) stock decreased by 38.31% to $290.0. The company's market cap stands at $3.7 billion.
- Sangamo Therapeutics (NASDAQ:SGMO) stock fell 36.51% to $0.47. The market value of their outstanding shares is at $106.5 million. As per the press release, Q1 earnings came out yesterday.
- Halozyme Therapeutics (NASDAQ:HALO) stock decreased by 25.95% to $49.31. The market value of their outstanding shares is at $6.0 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.